Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

4D Pharma Plc ADR (NQ: LBPS )

N/A UNCHANGED
Last Price Updated: 9:38 AM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 4D Pharma Plc ADR

4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq
From 4D pharma plc
Via Business Wire
Update on Suspension of Trading
From 4D pharma
Via Business Wire
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From 4D pharma plc
Via Business Wire
4D pharma to Present at the H.C. Wainwright Global Investment Conference
From 4D pharma
Via Business Wire
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
From 4D pharma
Via Business Wire
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
From 4D pharma plc
Via Business Wire
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor... 
Via FinancialNewsMedia
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
From 4D pharma
Via Business Wire
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
From 4D pharma
Via Business Wire
4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Disease
From 4D pharma plc
Via Business Wire
4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma
From 4D pharma
Via Business Wire
4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004
From 4D pharma plc
Via Business Wire
4D pharma to Present at the H.C. Wainwright BioConnect Conference
From 4D pharma plc
Via Business Wire
4D pharma appoints John Doyle as Chief Financial Officer
From 4D pharma plc
Via Business Wire
4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma
From 4D pharma plc
Via Business Wire
4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021
From 4D pharma plc
Via Business Wire
4D pharma to Participate in Jefferies London Healthcare Conference
From 4D pharma plc
Via Business Wire
4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit
From 4D pharma
Via Business Wire
4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021
From 4D pharma plc
Via Business Wire
4D pharma to Participate in Upcoming Virtual Investor Conferences in September
From 4D pharma
Via Business Wire
4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
From 4D pharma plc
Via Business Wire
4D pharma Announces $30 Million Credit Facility with Oxford Finance
From 4D pharma plc
Via Business Wire
4D pharma Announces Passing of Chief Financial Officer John Beck
From 4D pharma plc
Via Business Wire
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
From 4D pharma plc
Via Business Wire
4D pharma to Participate in Ladenburg Thalmann Healthcare Conference
From 4D pharma plc
Via Business Wire
4D pharma to Present at the Microbiome Movement Drug Development Summit
From 4D pharma plc
Via Business Wire
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
From 4D pharma plc
Via Business Wire
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
From 4D pharma plc
Via Business Wire
4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021
From 4D pharma plc
Via Business Wire
4D pharma Collaborates With Parkinson’s UK to Establish Patient Advisory Board
From 4D pharma plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.